{"id":"darbepoetin-alpha","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Hypertension"},{"rate":"5-15","effect":"Thrombovascular events (stroke, myocardial infarction, venous thromboembolism)"},{"rate":"10-20","effect":"Headache"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Injection site pain/reaction"},{"rate":"<1","effect":"Pure red cell aplasia (rare)"}]},"_chembl":{"chemblId":"CHEMBL1201566","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Darbepoetin alpha is a recombinant human erythropoietin analog with a longer half-life than epoetin alfa due to additional carbohydrate chains. It binds to erythropoietin receptors on erythroid progenitor cells in the bone marrow, promoting their proliferation, differentiation, and maturation into mature red blood cells. This mechanism increases hemoglobin levels and reduces the need for blood transfusions in patients with anemia.","oneSentence":"Darbepoetin alpha is an erythropoiesis-stimulating agent that binds to the erythropoietin receptor to stimulate red blood cell production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:37.647Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia associated with chronic kidney disease"},{"name":"Anemia in patients with non-myeloid malignancies receiving chemotherapy"},{"name":"Anemia of chronic disease"}]},"trialDetails":[{"nctId":"NCT01196715","phase":"PHASE3","title":"Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Barts & The London NHS Trust","startDate":"2010-11-01","conditions":"Myelodysplastic Syndrome","enrollment":360},{"nctId":"NCT05810311","phase":"PHASE2","title":"The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy","status":"NOT_YET_RECRUITING","sponsor":"Region Stockholm","startDate":"2025-06-01","conditions":"Diabetes Complications, Diabetes; Nephropathy (Manifestation)","enrollment":30},{"nctId":"NCT06466785","phase":"PHASE3","title":"A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis","status":"RECRUITING","sponsor":"Genexine, Inc.","startDate":"2024-01-25","conditions":"Anemia of Chronic Kidney Disease","enrollment":429},{"nctId":"NCT03446612","phase":"PHASE2","title":"Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-01-10","conditions":"Anaemia","enrollment":6},{"nctId":"NCT04432662","phase":"PHASE2","title":"Darbepoetin in Neonatal Encephalopathy Trial","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2021-05-28","conditions":"Neonatal Encephalopathy","enrollment":150},{"nctId":"NCT03071861","phase":"PHASE2","title":"Mild Encephalopathy in the Newborn Treated With Darbepoetin","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2017-12-01","conditions":"Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy Mild","enrollment":28},{"nctId":"NCT05699109","phase":"","title":"Erythropoiesis Stimulating Agents for Anemia Management in Egyptian Hemodialysis Patients","status":"COMPLETED","sponsor":"Helwan University","startDate":"2021-01-01","conditions":"Anemia of Chronic Kidney Disease, Chronic Renal Failure, Chronic Renal Failure Anemia","enrollment":127},{"nctId":"NCT04959578","phase":"PHASE4","title":"Comparison of Darbepoetin Alpha and Recombinant Human Erythropoietin for Treatment of Anemia in Children With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Rufaida Mazahir","startDate":"2018-02-01","conditions":"Anemia of Chronic Kidney Disease","enrollment":50},{"nctId":"NCT02439697","phase":"NA","title":"A Cohort Study of Conversion From Aranesp® to NESP® for the Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2015-11","conditions":"Anemia, End Stage Renal Failure on Dialysis","enrollment":50},{"nctId":"NCT00661505","phase":"PHASE3","title":"A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-05-14","conditions":"Anemia","enrollment":132},{"nctId":"NCT02049346","phase":"PHASE4","title":"Comparison Among Erythropoietin Stimulating Agents","status":"COMPLETED","sponsor":"Hamad Medical Corporation","startDate":"2012-03","conditions":"Anemia of End Stage Renal Disease","enrollment":327},{"nctId":"NCT00144755","phase":"PHASE3","title":"R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"Lymphoma Study Association","startDate":"2003-12","conditions":"Diffuse Large Cell Lymphoma","enrollment":600},{"nctId":"NCT01538771","phase":"PHASE2","title":"Intracoronary Darbepoetin-alpha to Reduce The Infarct Size and Post-Infarct Remodeling","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2009-11","conditions":"Myocardial Infarction","enrollment":80},{"nctId":"NCT00704652","phase":"","title":"Evaluation of Retinal Changes in Systemic Darbepoetin Alpha Treatment in Patients With Diabetes Mellitus","status":"TERMINATED","sponsor":"Medical University of Vienna","startDate":"2008-05","conditions":"Diabetic Retinopathy","enrollment":5},{"nctId":"NCT00526747","phase":"","title":"Erythropoietin Resistance in Anemia of Chronic Kidney Disease","status":"COMPLETED","sponsor":"Duke University","startDate":"2007-08","conditions":"Anemia, Kidney Failure, Erythropoietin","enrollment":32},{"nctId":"NCT00557817","phase":"PHASE2, PHASE3","title":"Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT)","status":"COMPLETED","sponsor":"University of Liege","startDate":"2004-03","conditions":"Hematological Malignancies","enrollment":125},{"nctId":"NCT00234143","phase":"PHASE2, PHASE3","title":"Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)","status":"UNKNOWN","sponsor":"St. Bartholomew's Hospital","startDate":"2004-10","conditions":"Myelodysplastic Syndromes","enrollment":360},{"nctId":"NCT00443339","phase":"PHASE2","title":"Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)","status":"UNKNOWN","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2006-12","conditions":"Myelodysplastic Syndromes","enrollment":99}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":238,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Aranesp"],"phase":"phase_3","status":"active","brandName":"Darbepoetin alpha","genericName":"Darbepoetin alpha","companyName":"Barts & The London NHS Trust","companyId":"barts-the-london-nhs-trust","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Darbepoetin alpha is a protein-based erythropoietin receptor agonist used to treat various conditions, including anemia of chronic kidney disease and anemia. It works by stimulating the erythropoietin receptor to promote the production of red blood cells.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2001-06-08T00:00:00.000Z","mah":"Amgen Europe B.V.","brand_name_local":"Aranesp","application_number":"EMEA/H/C/000332"}],"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}